| dc.contributor.author | Yılmaz, Yusuf | |
| dc.contributor.author | Kaya, Eda | |
| dc.date.accessioned | 2023-08-22T05:37:02Z | |
| dc.date.available | 2023-08-22T05:37:02Z | |
| dc.date.issued | 2023 | en_US |
| dc.identifier.citation | Yilmaz, Y., & Kaya, E. (2023). The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum, 4(2), I–II. https://doi.org/10.14744/hf.2022.2022.0044 | en_US |
| dc.identifier.issn | 1307-5888 | |
| dc.identifier.issn | 2757-7392 | |
| dc.identifier.uri | https://doi.org/10.14744/hf.2022.2022.0044 | |
| dc.identifier.uri | https://hdl.handle.net/11436/8087 | |
| dc.description.abstract | Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Kare Publishing | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease | en_US |
| dc.type | editorial | en_US |
| dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.contributor.institutionauthor | Yılmaz, Yusuf | |
| dc.identifier.doi | 10.14744/hf.2022.2022.0044 | en_US |
| dc.identifier.volume | 4 | en_US |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.startpage | I | en_US |
| dc.identifier.endpage | II | en_US |
| dc.relation.journal | Hepatology Forum | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
